Balasubramaniam R, Benaragama B V S H, Sri Ranganathan Shalini
Department of Pharmacology, Faculty of Medicine, University of Colombo, PO Box 271, Colombo 8, Sri Lanka.
Indian J Pediatr. 2014 Apr;81(4):362-7. doi: 10.1007/s12098-013-1024-9. Epub 2013 May 3.
To investigate the price and affordability of key essential medicines for children in Sri Lanka.
This national survey investigated the prices and affordability of 25 key essential medicines for children in private sector pharmacies using the WHO/Health Action International (HAI) medicine price methodology. Data were collected from a representative sample of 48 private sector pharmacies selected from 8 Provinces using a multistage clustered approach. At each pharmacy prices of originator brand (OB) and lowest priced generics (LPG) of the selected medicines were collected. Medicine prices were compared with international reference prices to obtain a median price ratio (MPR). Income of the lowest paid unskilled government worker was used to establish the affordability.
The median MPR of retail prices to patients was 3.7 for OB (range 0.23-20) and 1.35 for LPG (range 0.05-3.75). MPR >5 was observed for OBs of 5 medicines: ceftriaxone injection, diazepam injection, mebendazole syrup, mebendazole chewable tablet and metronidazole tablet whereas MPR >2.5 was observed only for LPGs of 3 medicines: chlorphenamine syrup, clotrimazole topical cream, and paracetamol syrup. Mean percent difference in price between OB and LPG products was 365 % (range -21, 2343). Rational treatment for acute infections such as mild lower respiratory tract infections and acute gastroenteritis seems to be affordable but treatment for chronic illnesses requiring liquid or inhaled dosage forms were largely unaffordable.
Intervention is needed to improve the economic access to key essential medicines for children indicated in the treatment of chronic diseases.
调查斯里兰卡儿童关键基本药物的价格及可负担性。
本全国性调查采用世界卫生组织/国际卫生行动组织(HAI)的药品价格方法,对私立药店中25种儿童关键基本药物的价格及可负担性进行调查。使用多阶段整群抽样方法,从8个省份选取48家私立药店作为代表性样本收集数据。在每家药店收集所选药物的原研品牌(OB)和最低价仿制药(LPG)的价格。将药品价格与国际参考价格进行比较,以获得中位数价格比(MPR)。用收入最低的非技术政府工作人员的收入来确定可负担性。
患者零售价格的MPR中位数,OB为3.7(范围0.23 - 20),LPG为1.35(范围0.05 - 3.75)。5种药物的OB观察到MPR>5:头孢曲松注射液、地西泮注射液、甲苯咪唑糖浆、甲苯咪唑咀嚼片和甲硝唑片;而仅3种药物的LPG观察到MPR>2.5:氯苯那敏糖浆、克霉唑外用乳膏和对乙酰氨基酚糖浆。OB和LPG产品之间的平均价格百分比差异为365%(范围-21, 2343)。对于轻度下呼吸道感染和急性肠胃炎等急性感染的合理治疗似乎是可负担的,但对于需要液体制剂或吸入剂型的慢性病治疗在很大程度上难以负担。
需要进行干预,以改善治疗慢性病所需儿童关键基本药物的经济可及性。